What is the Mankind Pharma PE ratio today?
Mankind Pharma's PE ratio is 45.4 at the 29 October 2026 close (₹2,469.30 a share): a market capitalisation of ₹1,01,982 crore divided by consolidated net profit attributable to shareholders of ₹2,249 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit attributable to shareholders (₹1,913 crore) it is 53.3.
What is the Mankind Pharma PB ratio (price to book value)?
Mankind Pharma's price-to-book (PB) ratio is 5.80 at the 29 October 2026 close: a market capitalisation of ₹1,01,982 crore divided by shareholders' equity (book value) of ₹17,582 crore on 30 September 2026. That is a book value of ₹425.72 per share against a share price of ₹2,469.30.
What is the Mankind Pharma ROE and ROCE?
In FY26, Mankind Pharma's return on equity (ROE) was 12.5% and its return on capital employed (ROCE) was 12.5%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 16.8% and ROCE 15.0%.
What is the Mankind Pharma market cap?
Mankind Pharma's market capitalisation was ₹1,01,982 crore (₹1.02 lakh crore) at the 29 October 2026 close: 41.3 crore shares at ₹2,469.30 each.
Is Mankind Pharma debt free?
No. Mankind Pharma had borrowings of ₹5,422 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.30. Its cash and current investments were ₹2,570 crore, so its net debt was ₹2,852 crore.
What is the Mankind Pharma EPS?
Mankind Pharma's basic earnings per share (EPS) were ₹46.35 in FY26, against ₹49.28 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹54.33.
What is the Mankind Pharma debt to equity ratio?
Mankind Pharma's debt-to-equity ratio was 0.30 on 30 September 2026: borrowings of ₹5,422 crore against total equity of ₹17,855 crore. A year earlier, on 30 September 2025, it was 0.54.
What is the Mankind Pharma promoter holding?
Promoters held 72.62% of Mankind Pharma on 30 September 2026, down 0.01 percentage points from 72.63% the previous quarter and down 0.05 percentage points from 72.67% a year earlier, according to the shareholding pattern filed with NSE.
What is the Mankind Pharma free cash flow?
In FY26, Mankind Pharma generated ₹3,121 crore of cash from operations and spent ₹737 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹2,384 crore. In FY25 it was ₹1,893 crore.
What is the Mankind Pharma net worth?
Mankind Pharma's net worth — shareholders' equity in its consolidated balance sheet — was ₹17,582 crore on 30 September 2026, up 15.0% from ₹15,286 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,01,982 crore at the 29 October 2026 close.
What is the Mankind Pharma book value per share?
Mankind Pharma's book value per share was ₹425.72 on 30 September 2026: shareholders' equity of ₹17,582 crore divided by the 41.3 crore shares in issue, up 15.0% from ₹370.30 a year earlier. The share price at the 29 October 2026 close was ₹2,469.30.
What are the Mankind Pharma latest quarterly results?
Mankind Pharma's latest results are for Q2 FY27 (July–September 2026), filed on 26 October 2026: consolidated net profit attributable to shareholders ₹711 crore, up 39.1% from ₹512 crore in Q2 FY26; revenue from operations ₹4,338 crore, up 17.3% year on year.
What is the Mankind Pharma shareholding pattern?
On 30 September 2026, Mankind Pharma's shares were held by promoters 72.62%, foreign portfolio investors (FII/FPI) 9.37%, domestic institutions (DII) 15.56% (including mutual funds at 11.31%) and retail and other non-institutional investors 2.45%. Over the year, FII holding was down 3.47 percentage points from 12.84% and DII holding was up 3.64 percentage points from 11.92%.
What is the Mankind Pharma revenue and profit in FY26?
In FY26 (April 2025–March 2026), Mankind Pharma's consolidated net profit attributable to shareholders was ₹1,913 crore, down 3.7% from ₹1,986 crore in FY25, on revenue from operations of ₹14,278 crore (up 17.0%). Over three years, from FY23, net profit was up 49.2%.
How does the Mankind Pharma PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Mankind Pharma's PE ratio is 53.3, the second highest of the four: Sun Pharma 36.8, Cipla 28.3 and Torrent Pharma 80.5, a peer average of 48.5. Each is the company's market capitalisation at that price divided by its FY26 net profit.
When are the Mankind Pharma next results?
Mankind Pharma has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
How does Mankind Pharma compare with its peers?
On FY26 consolidated figures, against Sun Pharma, Cipla and Torrent Pharma: Mankind Pharma's operating margin of 19.1% is the third highest of the four (Sun Pharma 25.3%, Cipla 16.6%, Torrent Pharma 24.6%; peer average 22.2%); its return on equity of 12.5% is the third highest of the four (Sun Pharma 14.7%, Cipla 11.8%, Torrent Pharma 27.1%; peer average 17.9%); its revenue growth over three years of 17.7% a year is the highest of the four (Sun Pharma 10.0% a year, Cipla 7.4% a year, Torrent Pharma 13.3% a year; peer average 10.2% a year).
Mankind Pharma vs Sun Pharma: how do they compare?
In FY26, Mankind Pharma earned net profit attributable to shareholders of ₹1,913 crore on revenue of ₹14,278 crore, against ₹11,479 crore on ₹58,462 crore for Sun Pharma. Mankind Pharma's operating margin was 19.1% (Sun Pharma 25.3%) and its return on equity 12.5% (Sun Pharma 14.7%). At the 29 October 2026 close, Mankind Pharma's market capitalisation was ₹1,01,982 crore against ₹4,22,517 crore for Sun Pharma, and its PE ratio on FY26 profit 53.3 against 36.8.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
